TITLE

Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients

AUTHOR(S)

Espíndola, Milena S.; Lima, Leonardo J. G.; Soares, Luana S.; Cacemiro, Maira C.; Zambuzi, Fabiana A.; de Souza Gomes, Matheus; Amaral, Laurence R.; Bollela, Valdes R.; Martins-Filho, Olindo A.; Frantz, Fabiani G.

PUB. DATE

December 2015

SOURCE

PLoS ONE;12/18/2015, Vol. 10 Issue 12, p1

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: Successful highly active antiretroviral therapy (HAART) has changed the outcome of AIDS patients worldwide because the complete suppression of viremia improves health and prolongs life expectancy of HIV-1+ patients. However, little attention has been given to the immunological profile of patients under distinct HAART regimens. This work aimed to investigate the differences in the immunological pattern of HIV-1+ patients under the first- or second-line HAART in Brazil. Methods: CD4+ T cell counts, Viral load, and plasma concentration of sCD14, sCD163, MCP-1, RANTES, IP-10, IL-1β, IL-6, TNF-α, IL-12, IFN-α, IFN-γ, IL-4, IL-5, and IL-10 were assessed for immunological characterization of the following clinical groups: Non-infected individuals (NI; n = 66), HIV-1+ untreated (HIV; n = 46), HIV-1+ treated with first-line HAART (HAART 1; n = 15); and HIV-1+ treated with second-line HAART (HAART 2; n = 15). Results: We found that the immunological biosignature pattern of HAART 1 is similar to that of NI individuals, especially in patients presenting slow progression of the disease, while patients under HAART 2 remain in a moderate inflammatory state, which is similar to that of untreated HIV patients pattern. Network correlations revealed that differences in IP-10, TNF-α, IL-6, IFN-α, and IL-10 interactions were primordial in HIV disease and treatment. Heat map and decision tree analysis identified that IP-10>TNF-α>IFN-α were the best respective HAART segregation biomarkers. Conclusion: HIV patients in different HAART regimens develop distinct immunological biosignature, introducing a novel perspective into disease outcome and potential new therapies that consider HAART patients as a heterogeneous group.

ACCESSION #

111828724

 

Related Articles

• The Importance of Potency and Durability in HIV Patient Antiretroviral Therapy Preferences: A Telephone Survey. Sherer Jr., Renslow D.; Fath, Michael J.; Da Silva, Barbara A.; Nicolau, Ana-Maria; Miller, Nancy L. // AIDS Patient Care & STDs;Dec2005, Vol. 19 Issue 12, p794 

  Patients who were receiving or had received antiretroviral therapy (ART) participated in 45-minute telephone interviews to evaluate the importance of major treatment attributes. A Likert scale was used to quantify and rate the importance of 9 ART attributes. Trade-off exercises allowed...

• Low-Level Viremia and Proviral DNA Impede Immune Reconstitution in HIV-1--Infected Patients Receiving Highly Active Antiretroviral Therapy. Ostrowski, Sisse R.; Katzenstein, Terese L.; Thim, Per T.; Pedersen, Bente K.; Gerstoft, Jan; Ullum, Henrik // Journal of Infectious Diseases;2/1/2005, Vol. 191 Issue 3, p348 

  Background. Immunological and virological consequences of low-level viremia in human immunodeficiency virus (HIV) type 1-infected patients receiving highly active antiretroviral therapy (HAART) remain to be determined. Methods. For 24 months, 101 HAART-treated, HIV-1-infected patients with HIV...

• Prevalence and Clinical Implications of Interactive Toxicity Beliefs Regarding Mixing Alcohol and Antiretroviral Therapies among People Living with HIV/AIDS. Kalichman, Seth C.; Amaral, Christina M.; White, Denise; Swetsze, Connie; Pope, Howard; Kalichman, Moira O.; Cherry, Chauncey; Eaton, Lisa // AIDS Patient Care & STDs;Jun2009, Vol. 23 Issue 6, p449 

  Alcohol use is a barrier to medication adherence. Beyond the cognitive effects of intoxication, people living with HIV/AIDS who believe that alcohol should not be mixed with their medications may temporarily stop taking medications when drinking. To examine the effects of alcohol-treatment...

• Use of complementary therapies to treat patients with HIV/AIDS. Palmer, Richard // Nursing Standard;8/20/2008, Vol. 22 Issue 50, p35 

  This article investigates the use of complementary and alternative medicine (CAM) in people living with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Since the beginning of the HIV/AIDS pandemic people living with HIV/AIDS have turned to CAM, either to...

• Contributions of Escherichia coli to Diarrhoea among HIV/AIDS Patients at a Hospital in Tropical West Africa. Tyodugh, Esther D.; Emanghe, Ubleni U.; Jombo, Godwin T.; Abraham, Ella B. // British Microbiology Research Journal;2012, Vol. 2 Issue 3, p175 

  Aims: To ascertain the contributions of Escherichia coli to diarrhea among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) in a HIV endemic community. Study Design: Hospital based cross-sectional study. Place and Duration of Study: Mkar Christian...

• HIV-associated early gastric adenocarcinoma successfully cured with surgery, and followed over eight years. Manfredi, Roberto; Sabbatani, Sergio; Fasulo, Giovanni // International Journal of STD & AIDS;Jul2007, Vol. 18 Issue 7, p501 

  An extremely rare case report of HIV-associated gastric adenocarcinoma surgically treated in the year 1998 in a 37-year-old male patient already HIV positive for 10 years, with a complete post-surgery disease-free follow-up of eight years, is described. An international literature search allowed...

• Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Therapy Containing Once-Daily Abacavir, Lamivudine, and Tenofovir DF in Treatment-Naive HIV-Infected Patients. Khanlou, Homayoun; Yeh, Vivian; Guyer, Bill; Farthing, Charles // AIDS Patient Care & STDs;Mar2005, Vol. 19 Issue 3, p135 

  Previous investigational data using abacavir (ABC), lamuvidine (3TC), and zidovudine has suggested the possibility of triple nucleoside analogue reverse transcriptase inhibitors (NRTI) therapy as an option in the treatment of HIV infection. We performed a pilot study to assess the potency of...

• Three-Class Antiretroviral Resistance in a Patient with Acute HIV-1 Infection. Gentz, Mark; Levin, Todd P.; Klibanov, Olga M.; Feingold, Anat; Condoluci, David V. // AIDS Patient Care & STDs;Nov2006, Vol. 20 Issue 11, p741 

  Antiretroviral resistance in treatment-naïve patients with HIV-1 infection is on the rise in both resource-rich and resource-poor countries. We report a case of three-class primary antiretroviral resistance detected by a genotypic assay in a 19-year-old woman with acute HIV-1 infection. Her...

• South Africans Win Some, Lose Some. Houlton, Sarah // Pharmaceutical Executive;Oct2003, Vol. 23 Issue 10, p24 

  Reports that the South African government has approved the provision of antiretroviral drugs to HIV-positive South Africans. Funding by the Global Fund to Fight AIDS, Malaria and Tuberculosis of an AIDS program in KwaZulu Natal.

Read the Article